Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

Open accessibility options menu
  • 24/7
  • Buzz
  • Startups
  • VC
  • Finance@
  • Work@
  • Innovation
  • Opinions
  • Search
  • cleanSearch
  • Accesabillty
  • calcalist logo
bycalcalist logo
  • Homepage
  • Tags search
  • UroGen

CTech 24/7

  • From red tape to revenue: The growth of business-to-government partnerships
  • “AI represents the most profound tectonic shift of our generation”
  • Intel to spin off networking group, stepping back from battle with Nvidia
  • Cyber unicorn Axonius acquires Cynerio in $180M deal to expand into healthcare security
More stories in CTech

UroGen

5 stories about UroGen
  • UroGen CEO Arie Belldegrun. Photo: Christopher Galluzzo

    ”Exits are not a Strategy. I Never put up a ‘For Sale’ Sign”

    23.05.20|Sophie Shulman and Golan HazaniArie Belldegrun, chairman of UroGen Pharma, talks about catching Covid-19 and gaining FDA approval in the midst of a global pandemic

  • Nasdaq. Photo: Shutterstock

    Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen

    24.04.19|CTechThe two companies will collaborate on the research of a “therapeutic area of mutual interest”

  • Nasdaq. Photo: Shutterstock

    Sustained Drug Release Company UroGen Aiming to Raise $150 Million on Nasdaq

    24.01.19|Lilach BaumerGoldman Sachs & Co. LLC, JP Morgan, and Jefferies are the joint bookrunners for the offering

  • UroGen CEO Ron Bentsur. Photo: Tomeriqo

    Sustained Drug Release Company UroGen Submits New Drug Application to FDA

    12.07.18|Amir RosenbaumKite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections

  • Allergan's Botox

    Allergan Partners with Urine Incontinence Treatment Company

    08.11.17|Lilach BaumerAllergan is conducting clinical trials for a Botox-based bladder treatment, using a sustained release gel developed by Israel-based UroGen

Load more
Ctech Logo
Twitter
Twitter
Facebook
Facebook
NewsLetter
Newsletter
Contact Us
Contact Us
Rss
Rss
About CTech Terms of Use Privacy Policy
Developed by YIT UI & UX by Basch_Interactive